📄 medicine
Perspectives of healthcare providers on differentiated service delivery of long-acting cabotegravir and rilpivirine in clinics and community settings in England: findings from the ILANA non-randomised implementation study
The ILANA study demonstrates that healthcare providers in England find the differentiated service delivery of long-acting injectable CAB + RPV in both clinic and community settings to be largely feasible, acceptable, and appropriate, provided that implementation prioritizes patient needs, equitable access, and provider ownership of the process.
Rosalie Hayes, Sara Paparini, Yuk Lam Wong, Joanne Haviland, Kyle Ring, Vanessa Apea, Bakita Kasadha, Tristan J. Barber (…)2026-06-28